Accel has led longevity startup Generation Lab’s $11 million seed round, Fortune has exclusively learned.

Among the top 1% of startup raises, the round will accelerate adoption of the SystemAge breakthrough aging diagnostic platform across 275+ clinics and tens of thousands of people worldwide

A new study featured in the journal Aging has found that combining oxytocin with an Alk5 inhibitor (OT+A5i) can greatly improve both lifespan and healthspan in older, frail male mice. The research, led by first author Cameron Kato and corresponding author Irina M. Conboy, an Aging-US Editorial Board Member from the University of California, Berkeley, showed that this treatment offered significant rejuvenating effects in males but not in females, suggesting that biological differences between the sexes may play a crucial role in how aging therapies work.

Health is often taken for granted until sickness strikes. We frequently overlook the value of waking up pain-free and enjoying food and drink without a second thought.

Like a tree's growth rings, humans have markers of aging, and leaders of a San Francisco startup with UC Berkeley roots say clues can be found in the human equivalents of leaves, bark and seeds.

Generation Lab, the first longevity platform to measurably extend the human lifespan, today announced the general availability of its groundbreaking offering: the first platform that measures aging speed, biomarkers for disease, and top aging factors. It offers personalized action plans aimed at cell regeneration across key organs and systems to slow or even reverse aging.

When Generation Lab officially launches in the spring this year, the company will offer what it claims is the first clinically-based test that uses epigenetic information to measure biological age and disease risk. The company is currently testing its product internally and plans to officially launch its product in the second quarter of 2024.

More people are taking extra steps to ensure optimal health as they age. That’s according to Alina Su, CEO of precision medicine and health tech company Generation Lab, at Fortune’s Brainstorm Health conference in Dana Point, Calif., last week.

Given the long list of major catastrophes in the world — melting polar ice, raging wars, the disappearance of early-bird specials, etc. — I’m not sure why so many people want to live forever. But they do, and the multibillion-dollar longevity industry is booming.

San Francisco-based longevity startup Generation Lab has emerged from stealth – securing pre-seed funding and unveiling its mission to extend human healthspan. With its roots in the University of California at Berkeley, the company has developed an at-home cheek-swab aging test, which measures the “molecular disbalance” that indicates rate of aging and risk of disease.

Generation Lab, a San Francisco, CA-based provider of a test based on clinically relevant biological evidence, raised an undisclosed amount to Pre-Seed funding.

Generation Lab – a company that is extending the human healthspan with the first test based on biomedical evidence that measures an individual’s biological age progression – has officially launched today out of stealth. And the company is announcing its pre-seed funding and the opening of its test kit waitlist.

More people are eager to find out their age—and not the one on their birth certificate. A plethora of longevity-based companies are offering biological age tests—which may reveal more about the future of our health than the number we celebrate annually. Using epigenetic markers, many biological age tests measure the impact of lifestyle, environment, and behavior on aging. With more awareness of the role people play in how fast they’re aging, they can adjust their diet, exercise, social connectedness, and sleep.